USD
$0.00
(0.00%
)At Close (As of Sep 26, 2025)
$289.47M
Market Cap
-
P/E Ratio
-0.1
EPS
$2.23
52 Week High
$1.12
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $100M |
Total Revenue | $180M |
Cost Of Revenue | $81M |
Costof Goods And Services Sold | $81M |
Operating Income | -$14M |
Selling General And Administrative | $76M |
Research And Development | $59M |
Operating Expenses | $114M |
Investment Income Net | - |
Net Interest Income | -$8.9M |
Interest Income | - |
Interest Expense | $8.9M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.9M |
Income Before Tax | -$21M |
Income Tax Expense | $205K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$21M |
Comprehensive Income Net Of Tax | - |
Ebit | -$12M |
Ebitda | -$9.9M |
Net Income | -$21M |
Field | Value (USD) |
---|---|
Total Assets | $201M |
Total Current Assets | $152M |
Cash And Cash Equivalents At Carrying Value | $20M |
Cash And Short Term Investments | $20M |
Inventory | $38M |
Current Net Receivables | $30M |
Total Non Current Assets | $49M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | $1.3M |
Investments | - |
Long Term Investments | - |
Short Term Investments | $60M |
Other Current Assets | $3.6M |
Other Non Current Assets | - |
Total Liabilities | $144M |
Total Current Liabilities | $64M |
Current Accounts Payable | $22M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $22M |
Total Non Current Liabilities | $80M |
Capital Lease Obligations | $14M |
Long Term Debt | $65M |
Current Long Term Debt | $19M |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $98M |
Other Current Liabilities | $19M |
Other Non Current Liabilities | $3.9M |
Total Shareholder Equity | $56M |
Treasury Stock | - |
Retained Earnings | -$1.1B |
Common Stock | $186K |
Common Stock Shares Outstanding | $185M |
Field | Value (USD) |
---|---|
Operating Cashflow | $11M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.9M |
Capital Expenditures | $2.8M |
Change In Receivables | - |
Change In Inventory | $7M |
Profit Loss | - |
Cashflow From Investment | -$8.1M |
Cashflow From Financing | $5M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$21M |
Field | Value (USD) |
---|---|
Gross Profit | $100M |
Total Revenue | $180M |
Cost Of Revenue | $81M |
Costof Goods And Services Sold | $81M |
Operating Income | -$14M |
Selling General And Administrative | $76M |
Research And Development | $59M |
Operating Expenses | $114M |
Investment Income Net | - |
Net Interest Income | -$8.9M |
Interest Income | - |
Interest Expense | $8.9M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.9M |
Income Before Tax | -$21M |
Income Tax Expense | $205K |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$21M |
Comprehensive Income Net Of Tax | - |
Ebit | -$12M |
Ebitda | -$9.9M |
Net Income | -$21M |
Sector: HEALTHCARE
Industry: MEDICAL DEVICES
Cerus Corporation (CERS) is a leading biomedical products company dedicated to enhancing blood safety through its innovative INTERCEPT Blood System, which effectively inactivates pathogens in blood components. Based in Concord, California, Cerus leverages cutting-edge technology to address critical needs in transfusion medicine, offering solutions that are vital for patient safety. With a growing portfolio and a commitment to advancing blood safety protocols globally, Cerus is well-positioned within the healthcare sector, catering to the increasing demand for safe blood products.